cd19-ucart

Relapse/Recurrence

Beijing Boren HospitalCell therapyPhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

6 Active assets in the Relapse/Recurrence cohort.

Asset / Sponsor	Phase	Rating
Cytosin-Arabinosid Shenzhen University General Hospital	Phase 2	CCC
Venetoclax Shenzhen University General Hospital	Phase 2	CCC
Azacitidine Children's Hospital of Soochow University	Phase 2	CCC
Ifosfamide Zhejiang Cancer Hospital	Phase 2	CCC
ETOPOSIDE Zhejiang Cancer Hospital	Phase 2	CCC

View all 10 →

Same molecule, other indications

cd19-ucart is also rated in:

B-Cell Acute Lymphoblastic Leukemia, AdultDormant

BBB

Indicative ·

72 / 100

B-cell non-Hodgkin lymphomaDormant

BB

Indicative ·

71 / 100

B-cell acute lymphoblastic leukemiaDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.